Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Japanese encephalitis virus vaccine + Advax is a recombinant protein vaccine candidate developed by Vaxine. It consists of recombinant flavivirus antigens formulated with Vaxine's proprietary Advax adjuvant, which is based on delta-inulin. The vaccine is designed to provide broad-spectrum protection against Japanese encephalitis virus (JEV) and related flaviviruses that cause encephalitis. Preclinical data suggests that the formulation induces robust immune responses and offers cross-protection against Murray Valley encephalitis virus (MVEV), Kunjin virus, and West Nile Virus (WNV). The use of the Advax adjuvant is intended to enhance the vaccine's immunogenicity while maintaining a high safety profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on japanese encephalitis virus vaccine + Advax.